TY - CHAP
T1 - Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease
AU - Lista, Simone
AU - Zetterberg, Henrik
AU - O’Bryant, Sid E.
AU - Blennow, Kaj
AU - Hampel, Harald
N1 - Publisher Copyright:
© 2017 by Taylor & Francis Group, LLC.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - In general, a biomarker denes a biological process or disease characteristic that is objectively measured (Biomarkers Denitions Working Group, 2001). Such measurements may be used for diagnostic purposes, but also to study physiological or pathophysiological mechanisms and to evaluate desired pharmacodynamic eects or side eects of pharmacological treatments. According to Biomarkers Denitions Working Group: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, the ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically con-rmed cases as well as have a diagnostic accuracy of at least 80% (e Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and National Institute on Aging Working Group, 1998). With respect to clinically relevant questions, such as detection, diagnosis, prediction and treatment of a given disease, biomarkers may serve certain distinct functions (Hampel et al., 2010b; Hampel and Lista, 2013), which are detailed in Table 51.1.
AB - In general, a biomarker denes a biological process or disease characteristic that is objectively measured (Biomarkers Denitions Working Group, 2001). Such measurements may be used for diagnostic purposes, but also to study physiological or pathophysiological mechanisms and to evaluate desired pharmacodynamic eects or side eects of pharmacological treatments. According to Biomarkers Denitions Working Group: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, the ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically con-rmed cases as well as have a diagnostic accuracy of at least 80% (e Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and National Institute on Aging Working Group, 1998). With respect to clinically relevant questions, such as detection, diagnosis, prediction and treatment of a given disease, biomarkers may serve certain distinct functions (Hampel et al., 2010b; Hampel and Lista, 2013), which are detailed in Table 51.1.
UR - http://www.scopus.com/inward/record.url?scp=85053973026&partnerID=8YFLogxK
U2 - 10.1201/9781315381572
DO - 10.1201/9781315381572
M3 - Chapter
AN - SCOPUS:85053973026
SN - 9781498703123
SP - 528
EP - 538
BT - Dementia, Fifth Edition
PB - CRC Press
ER -